BioSpace News Archive

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and...

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, today announced the publication of its positive Measles and Rubella (MR) Phase 1/2 trial data in The Lancet Medical Journal.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that company management will present at the Citizens JMP Life Sciences Conference taking place in New York, NY, from May 13 – 14, 2024.

Chimerix reported financial results for the first quarter ended March 31, 2024 and provided an operational update.

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.

Neurocrine Biosciences, Inc. announced its financial results for the first quarter ended March 31, 2024 and provided an update on its 2024 financial guidance.

REGENXBIO Inc. announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent operational highlights.

Luxa Biotechnology, a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute in Rensselaer, New York, announced receipt of a $4 million grant from the California Institute for Regeneration Medicine to support the ongoing Phase 1/2a study of RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration.

AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society International Conference, in San Diego, CA from May 17 - 22, 2024.

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024.